Vaccine therapy in non—small-cell lung cancer
- 43 Downloads
Lung cancer is the leading cause of death from cancer worldwide. First-line therapy is based on stage at diagnosis can include chemotherapy, radiation, and surgery. Despite advances, the prognosis for advanced-stage lung cancer is very poor. Vaccines with the capability to activate the host immune system may have a role in second-line therapy. Advances in the understanding of cellular and molecular immunology are forming the basis for improving vaccine therapy. Most trials to date have demonstrated safety but inconsistent efficacy. Further research is needed to enhance this potential.
KeywordsMUC1 Mucin Vaccine Site Logous Tumor Cell Ogous Tumor Quamous Cell Carcinom
Unable to display preview. Download preview PDF.
References and Recommended Reading
- 1.National Cancer Institute. Available at http://www.cancer.gov/cancertopics/types/lung. Accessed February 2007.
- 2.Travis WD, Colby TV, Corrin B, et al.: Histological Typing of Lung and Pleural Tumours, edn 3. Berlin: Springer-Verlag; 1999.Google Scholar
- 34.Salgia R, Lynch T, Skarin A, et al.: Vaccination with irradiated autologous tumor cells engineered to secrete granulocyte-macrophage colony-stimulation factor augments antitumor immunity in some patients with metastatic non—small-cell lung carcinoma. J Clin Oncol 2003, 21:624–630.PubMedCrossRefGoogle Scholar